Abstract:Multiple myeloma (MM) is an incurable B-cell malignancy. High-dose chemotherapy with stem cell support has achieved higher response rates than conventional therapy, but few patients remain in long-term remission. Arsenic trioxide (As2O3) is an effective treatment for acute promyelocytic leukemia. Current clinical studies are investigating arsenic as a therapeutic agent for malignancies. The mechanism of cytotoxicity inducted by As2O3 has not been known thoroughly. Constitutively activated NF-κB is a characteristic of different tumor entities including MM clones and malignant plasma cells from MM patients. It plays an important role in maintaining tumor cell proliferation and protecting cell from apoptosis. The study was to explore the possible mechanism of As2O3 effects on MM lines. Materials and methods: The human MM cell lines of KM3 and RPMI8226 were provided by Hematology Institution of Zhejiang University. The concentration of As2O3 in cell culture system was from 0.5μmol/L to 20μmol/L, 24 hours was selected as the termination point of cell culture. Cell culture without As2O3 and first-antibody-dismissed test were enrolled as controls. Both of the MM lines were treated with As2O3 in various concentrations. The restrained proliferation was observed by drawing growth curve. MTT bioassay was used to examine the effect of As2O3 on cell growth and the concentration of 50% growth inhibition( IC50) calculated respectively. Apoptosis and changes of IκB-α protein was observed by flow cytometry(FCM). Changes and subcellular localization of IκB-α protein were observed by fluorescence microscopy. Western blot was also used to analyze the expression of NF-κB in nuclear. Results: As2O3 inhibited the proliferation of both MM lines, and IC50 of KM3 and RPMI8226 was 9.61μmol/L and 8.01μmol/L respectively. After exposure to As2O3, both of the lines were induced to apoptosis. With As2O3 concentration varied from 0.5μmol/L to 20μmol/L the apoptosis rate of KM3 and RPMI8226 was concentration-dependent measured by FCM. After 24 hours treated with 20μmol/L As2O3, the apoptosis rate of KM3 cells was 41.18% while that of RPMI8226 was 65.25%. It seemed that RPMI8226 cell was more sensitive to As2O3. FCM analysis showed a significant increase in the percentage of G2/M phase cells, from 13.74% to 41.72%, and a decrease percentage of S phase cells from 35.11% to 23.96%. The level of IκB-α in cytoplasm was down-regulated after As2O3 stimulation in both cell lines. The down-regulation of IκB-α from 79.68% to 51.57% was confirmed by FCM in KM3 treated with 10μmol/L As2O3 (p<0.01), the effect was concentration-dependent. While the IκB-α in RPMI8226 changed from 79.72% to 34.08% (p<0.01). Immunofluorescence assay showed that IκB-α localized in cytoplasm mostly. The level of IκB-α protein was down-regulated after As2O3 stimulation. The results showed that KM3 and RPMI8226 lines expressed constitutively activity NF-κB and As2O3 down-regulated the constitutive expression of NF-κB in both cell lines but with different kinetics. Conclusions: As2O3 could not only inhibit the proliferation but also induce apoptosis of KM3 and RPMI8226 cells. The mechanisms of its effect on MM cells may include decreasing the constitutive activity of NF-κB, subsequently down-regulating the expression of various gene products controlled by NF-κB, thus inducing apoptosis in MM cells. As2O3 could inhibit the proliferation of MM cells by changing MM cell cycle and inducing G2/M phase arrest.

Curcumin Synergistically Enhances the Cytotoxicity of Arsenic Trioxide in U266 Cells by Increasing Arsenic Uptake

Mechanism Of Arsenic Trioxide-Induced Apoptosis On Multiple Myeloma Cells.

Mechanisms of Arsenic Trioxide Induced Tumor Cell Apoptosis in Myelodysplastic Syndrome Mice Model in Vivo

Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.

Cucurbitacin B Synergistically Enhances the Apoptosis-Inducing Effect of Arsenic Trioxide by Inhibiting STAT3 Phosphorylation in Lymphoma Ramos Cells

Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.

Ascorbic Acid Sensitizes Colorectal Carcinoma to the Cytotoxicity of Arsenic Trioxide via Promoting Reactive Oxygen Species-Dependent Apoptosis and Pyroptosis

Effects and Mechanism of Arsenic Trioxide in Combination with Rmhtrail in Multiple Myeloma.

Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition

Arsenic trioxide(ATO)induces multiple myeloma cell line U266 apoptosis in vitro

Arsenic Trioxide-Mediated Growth Inhibition of Myeloma Cells Is Associated with An Extrinsic Signaling Pathway Involved in Caspase 3 and Caspase 8.

Arsenic Trioxide And Cisplatin Synergism Increase Cytotoxicity In Human Ovarian Cancer Cells: Therapeutic Potential For Ovarian Cancer

SurvivinT34A Increases the Therapeutic Efficacy of Arsenic Trioxide in Mouse Hepatocellular Carcinoma Models.

Effect of combination of arsenic trioxide and interferon on the expression of TRAIL and its receptor in U266 cells

The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells.

Arsenic Trioxide Enhances the Chemotherapeutic Efficiency of Cisplatin in Cholangiocarcinoma Cells Via Inhibiting the 14-3-3ε-mediated Survival Mechanism

Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.

[Mechanism of Arsenic Trioxide-Induced Cytotoxicity on Multiple Myeloma Cells].

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia